| pubmed-article:12750840 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12750840 | lifeskim:mentions | umls-concept:C1516213 | lld:lifeskim |
| pubmed-article:12750840 | lifeskim:mentions | umls-concept:C0025519 | lld:lifeskim |
| pubmed-article:12750840 | lifeskim:mentions | umls-concept:C0015133 | lld:lifeskim |
| pubmed-article:12750840 | lifeskim:mentions | umls-concept:C0086444 | lld:lifeskim |
| pubmed-article:12750840 | lifeskim:mentions | umls-concept:C0450442 | lld:lifeskim |
| pubmed-article:12750840 | lifeskim:mentions | umls-concept:C0332293 | lld:lifeskim |
| pubmed-article:12750840 | lifeskim:mentions | umls-concept:C0733406 | lld:lifeskim |
| pubmed-article:12750840 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:12750840 | pubmed:dateCreated | 2003-7-28 | lld:pubmed |
| pubmed-article:12750840 | pubmed:abstractText | The study was undertaken to determine the metabolism of dexrazoxane (ICRF-187) to its one-ring open hydrolysis products and its two-rings opened metal-chelating product ADR-925 in cancer patients with brain metastases treated with high-dose etoposide. In this phase I/II trial dexrazoxane was used as a rescue agent to reduce the extracerebral toxicity of etoposide. | lld:pubmed |
| pubmed-article:12750840 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12750840 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12750840 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12750840 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12750840 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12750840 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12750840 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12750840 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12750840 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12750840 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12750840 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:12750840 | pubmed:issn | 0344-5704 | lld:pubmed |
| pubmed-article:12750840 | pubmed:author | pubmed-author:LangerSeppo... | lld:pubmed |
| pubmed-article:12750840 | pubmed:author | pubmed-author:SehestedMaxwe... | lld:pubmed |
| pubmed-article:12750840 | pubmed:author | pubmed-author:HasinoffBrian... | lld:pubmed |
| pubmed-article:12750840 | pubmed:author | pubmed-author:SchroederPatr... | lld:pubmed |
| pubmed-article:12750840 | pubmed:author | pubmed-author:JensenPeter... | lld:pubmed |
| pubmed-article:12750840 | pubmed:author | pubmed-author:HoflandKennet... | lld:pubmed |
| pubmed-article:12750840 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12750840 | pubmed:volume | 52 | lld:pubmed |
| pubmed-article:12750840 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12750840 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12750840 | pubmed:pagination | 167-74 | lld:pubmed |
| pubmed-article:12750840 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:12750840 | pubmed:meshHeading | pubmed-meshheading:12750840... | lld:pubmed |
| pubmed-article:12750840 | pubmed:meshHeading | pubmed-meshheading:12750840... | lld:pubmed |
| pubmed-article:12750840 | pubmed:meshHeading | pubmed-meshheading:12750840... | lld:pubmed |
| pubmed-article:12750840 | pubmed:meshHeading | pubmed-meshheading:12750840... | lld:pubmed |
| pubmed-article:12750840 | pubmed:meshHeading | pubmed-meshheading:12750840... | lld:pubmed |
| pubmed-article:12750840 | pubmed:meshHeading | pubmed-meshheading:12750840... | lld:pubmed |
| pubmed-article:12750840 | pubmed:meshHeading | pubmed-meshheading:12750840... | lld:pubmed |
| pubmed-article:12750840 | pubmed:meshHeading | pubmed-meshheading:12750840... | lld:pubmed |
| pubmed-article:12750840 | pubmed:meshHeading | pubmed-meshheading:12750840... | lld:pubmed |
| pubmed-article:12750840 | pubmed:meshHeading | pubmed-meshheading:12750840... | lld:pubmed |
| pubmed-article:12750840 | pubmed:meshHeading | pubmed-meshheading:12750840... | lld:pubmed |
| pubmed-article:12750840 | pubmed:meshHeading | pubmed-meshheading:12750840... | lld:pubmed |
| pubmed-article:12750840 | pubmed:meshHeading | pubmed-meshheading:12750840... | lld:pubmed |
| pubmed-article:12750840 | pubmed:meshHeading | pubmed-meshheading:12750840... | lld:pubmed |
| pubmed-article:12750840 | pubmed:meshHeading | pubmed-meshheading:12750840... | lld:pubmed |
| pubmed-article:12750840 | pubmed:meshHeading | pubmed-meshheading:12750840... | lld:pubmed |
| pubmed-article:12750840 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:12750840 | pubmed:articleTitle | Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide. | lld:pubmed |
| pubmed-article:12750840 | pubmed:affiliation | Faculty of Pharmacy, University of Manitoba, 50 Sifton Road, R3T 2N2, Winnipeg, Manitoba, Canada. | lld:pubmed |
| pubmed-article:12750840 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12750840 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
